Haitong International: Maintains Shanghai Pharmaceuticals (02607.HK) "outperform" rating with a target price of HK$13.73.

Wisdom Finance APP learned that Haitong International released a research report stating that Shanghai Pharmaceuticals (02607.HK) released its first quarter performance in 2025. The bank used cash flow discount models and cash flows from FY26 to FY33 for valuation, based on a WACC of 6.2%, perpetual growth rate of 3%, and a 60% discount of Hong Kong shares to A-shares (all unchanged). The company's target price is maintained at HKD13.73, with a "outperform the market" rating. The current stock price corresponds to 7.4/6.7 times P/E for 2025/26 respectively.